Lantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET

Company Participants

Mark Kinarney - VP of IR
Brian Markison - CEO
Paul Blanchfield - President
Bob Marshall - CFO
Jeff Humphrey - Chief Medical Officer
Amanda Morgan - Chief Commercial Officer

Conference Call Participants

Anthony Petrone - Mizuho Group
Roanna Ruiz - Leerink Partners
Richard Newitter - Truist Securities
Matt Taylor - Jefferies
Tara Bancroft - TD Cowen
Larry Solow - CJS Securities
Yuan Zhi - B. Riley
David Turkaly - Citizens JMP Securities LLC
Justin Walsh - Jones Trading
Andy Hsieh - William Blair
Kemp Dolliver - Brookline Capital Markets
Richard Newitter - Truist Securities

Operator

Good morning. Welcome to the Lantheus Fourth Quarter and Full Year [ph] 2024 Conference Call. This is your operator for today's call.

Please note that all lines have been placed on mute to limit background noise. This call is being recorded. A replay will be available in the investors section of the company's website approximately two hours after the completion of the call and will be archived for at least 30 days.

I'll now turn the call over to your host for today. Mark Kinarney, Vice President of Investor Relations. Mark?

Mark Kinarney

Thank you. Good morning and welcome to today's call. With me today are Brian Markison, our CEO, Paul Blanchfield, our president, Bob Marshall, our CFO, Jeff Humphrey, our Chief Medical Officer, and Amanda Morgan, our Chief Commercial Officer.

We will begin the call with prepared remarks and then open the call for Q&A. This morning we issued a press release which was furnished to the SEC under Form 8K reporting our second quarter 2024 results. The release and today's slide presentation are in the investors section of our website.

Any comments made during our call could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties which are detailed in our SEC filings. Discussions during this call will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the investors section of our website.

I will now turn the call over to our CEO, Brian.

Brian Markison

Thank you, Mark, and good morning, everyone. At Lantheus, we are the leading radiopharmaceutical-focused company with a clear purpose to find, fight, and follow disease to deliver better patient outcomes. Last quarter, we outlined our strategy to enhance our leadership by maximizing the value of our existing portfolio and expanding our innovative pipeline of radiopharmaceuticals through focused business development and M&A, all while sustaining a strengthening and attractive financial profile.